

17. **Klein, R., Peto, T., Bird, A., C., et al.:** The Epidemiology of Age-Related Macular Degeneration. *Am J Ophthalmol*, 2004; 137: 486–495.
18. **Klein, R., Klein, B., E., Lee, K., E.:** Changes in Visual Acuity in a Population Over a 15-year Period: The Beaver Dam Eye Study. *Am J Ophthalmol*, 2006; 142: 539.e1–539.e13.
19. **van Leeuwen, R., Ikram, M., K., Vingerling, J., R., et al.:** Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam study. *Invest Ophthalmol Vis Sci*, 2003; 44: 3771–3777.
20. **Mitchell, P., Smith, W., Attebo, K., et al.:** Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. *Ophthalmology*, 1995; 102: 1450–60.
21. **Mitchell, P., Wang, J., J., Foran, S., et al.:** Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. *Ophthalmology*, 2002; 109: 1092–1097.
22. **Roberts, J., E.:** Ocular phototoxicity. *J Photochem Photobiol B*, 2001; 64: 136–143.
23. **Rosenberg, T.:** Prevalence and causes of blindness in Greenland. *Arctic Med Res*, 1987; 46: 13–17.
24. **Rosenberg, T.:** Prevalence of blindness caused by senile macular degeneration in Greenland. *Arctic Med Res*, 1987; 46: 64–70.
25. **Sarks, S., H.:** Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium. *Aust J Ophthalmol*, 1982; 10: 91–97.
26. **Smith, W., Assink, J., Klein, R, et al.:** Risk factors for age-related macular degeneration: Pooled findings from three continents. *Ophthalmology* 2001;108:697–704.
27. **Sosna, T.:** Epidemiologie a rizikové faktory VPMD. In Kolář, P.: Věkem podmíněná makulární degenerace, Praha: Grada, 2008, s. 148.
28. **Tomany, S., C., Wang, J., J., van Leeuwen, R., et al.:** Risk factors for incident age-related macular degeneration: Pooled findings from three continents. *Ophthalmology*, 2004; 111: 1280–1287.
29. **Tong, L., Lai, M., Klein, R., et al.:** Prevalence of age-related maculopathy (ARM) in a population- based cohort of adult Latinos: The Los Angeles Latino Eye Study (LALES). *Invest Ophthalmol Vis Sci*, 2003; 44: 2107.
30. **Vingerling, J., R., Dielemans, I., Bots, M., L., et al.:** Age-related macular degeneration is associated with atherosclerosis. The Rotterdam study. *Am J Epidemiol*, 1995; 142: 404–409.
31. **Vingerling, J., R., Dielemans, I., Hofman, A., et al.:** The prevalence of age-related maculopathy in the Rotterdam Study. *Ophthalmology*, 1995; 102: 205–210.
32. **Wang, J., J., Foran, S., Smith, W., et al.:** Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: The Blue Mountains Eye study cohort. *Arch Ophthalmol*, 2003; 121: 658–663.
33. **Wang, J., J., Rochtchina, E., Lee, A., J., et al.:** Ten-Year Incidence and Progression of Age-Related Maculopathy The Blue Mountains Eye Study. *Ophthalmology*, 2007; 114: 92–98.

*MUDr. Petr Kolář, Ph.D.
Oční klinika LF MU a FN Brno
Jihlavská 20
625 00 Brno
pkolar@fnbrno.cz*

OZNÁMENÍ

Oznamujeme oftalmologické veřejnosti, že prof. MUDr. Pavel Rozsíval, CSc., FEBO, byl v Talinu dne 19. června 2010 zvolen viceprezidentem Oftalmologické sekce UEMS

PŘIPOMÍNKA

Upozorňujeme čtenáře, že sdělení „Refrakční nitrooční čočky společnosti Alcon“ MUDr. Angeliky Fialové, zveřejněné ve druhém čísle našeho časopisu na str. č. 92, je neoponovaná hrazená publikace.